We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > COVI-VAC

News List

Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies prnewswire
September 28, 2021
Codagenix Inc., a clinical-stage biotechnology company pioneering a novel platform for vaccines and oncolytic virus therapies, today announced that their novel intranasal COVI-VAC vaccine...
First patient dosed with COVI-VAC, an intranasal COVID-19 vaccine candidate europeanpharmaceuticalreview
January 14, 2021
The trial will assess the safety and immunogenicity of a single intranasal dose of COVI-VAC in 48 healthy volunteers in the UK.
Codagenix, Serum Institute of India Announce Trial Single Dose Vaccine for COVID-19 americanpharmaceuticalreview
January 05, 2021
Codagenix and the Serum Institute of India (SIIPL) announced a Phase 1 clinical trial of COVI-VAC received regulatory approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) and has commenced in London, UK.
Green light for UK trial of nasal coronavirus vaccine pharmatimes
December 16, 2020
Open Orphan and Codagenix have received approval from the UK’s independent Medicines and Healthcare Products Regulatory Agency (MHRA) to conduct a Phase I study of its COVID-19 vaccine.